Home/Filings/4/0001209191-22-014626
4//SEC Filing

Shacham Sharon 4

Accession 0001209191-22-014626

CIK 0001503802other

Filed

Mar 1, 7:00 PM ET

Accepted

Mar 2, 3:20 PM ET

Size

12.1 KB

Accession

0001209191-22-014626

Insider Transaction Report

Form 4
Period: 2022-02-28
Shacham Sharon
CSO & Pres. Res. & Dev.
Transactions
  • Sale

    Common Stock

    2022-02-28$10.24/sh6,226$63,739713,757 total(indirect: By Spouse)
  • Sale

    Common Stock

    2022-02-28$10.24/sh6,226$63,739898,131 total
  • Award

    Stock Option (right to buy)

    2022-02-28+27,00027,000 total(indirect: By Spouse)
    Exercise: $10.33Exp: 2032-02-27Common Stock (27,000 underlying)
  • Award

    Common Stock

    2022-02-28+21,000719,983 total(indirect: By Spouse)
Footnotes (5)
  • [F1]This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
  • [F2]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F3]Represents the award of restricted stock units ("RSUs") to the spouse of the reporting person pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.
  • [F4]This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.
  • [F5]This option was granted to the spouse of the reporting person on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Issuer

Karyopharm Therapeutics Inc.

CIK 0001503802

Entity typeother

Related Parties

1
  • filerCIK 0001588438

Filing Metadata

Form type
4
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 3:20 PM ET
Size
12.1 KB